NASDAQ:TNXP Tonix Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $1.58 -0.08 (-4.82%) (As of 06/30/2022 12:00 AM ET) Add Compare Share Today's Range$1.53▼$1.6250-Day Range$1.66▼$70.7252-Week Range$1.53▼$36.48Volume2.29 million shsAverage Volume3.47 million shsMarket Capitalization$26.40 millionP/E RatioN/ADividend YieldN/APrice Target$41.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TNXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TNXP Stock Forecast (MarketRank)Overall MarketRank™1.76 out of 5 starsMedical Sector851st out of 1,433 stocksPharmaceutical Preparations Industry420th out of 684 stocksAnalyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingTonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.60, Tonix Pharmaceuticals has a forecasted upside of 2,532.9% from its current price of $1.58.Amount of Analyst CoverageTonix Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesTonix Pharmaceuticals has received 336 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTonix Pharmaceuticals has received 144 “underperform” votes. (Add your “underperform” vote.)Community SentimentTonix Pharmaceuticals has received 70.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote “Outperform” if you believe TNXP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTonix Pharmaceuticals does not currently pay a dividend.Dividend GrowthTonix Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tonix Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Tonix Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 22.87% of the stock of Tonix Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tonix Pharmaceuticals are expected to decrease in the coming year, from ($6.25) to ($6.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tonix Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tonix Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTonix Pharmaceuticals has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tonix Pharmaceuticals (NASDAQ:TNXP)Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.Read More TNXP Stock News HeadlinesJune 30, 2022 | americanbankingnews.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Decrease in Short InterestJune 25, 2022 | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded to Sell at StockNews.comJune 24, 2022 | finance.yahoo.comNew to The Street TV / Newsmax TV Announces its Six Interviews for This Week's TV Broadcast, Episode #358, June 26, 2022, 10-11 AM ETJune 23, 2022 | americanbankingnews.comReviewing Tonix Pharmaceuticals (NASDAQ:TNXP) & Arvinas (NASDAQ:ARVN)June 21, 2022 | seekingalpha.comIs Tonix Pharma's Stock A Buy Or Sell After Buyback Plan Announcement?June 15, 2022 | finance.yahoo.comMarket check: Stocks pare gains following Fed rate hikeJune 13, 2022 | americanbankingnews.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Increase in Short InterestJune 6, 2022 | finance.yahoo.comTonix Pharmaceuticals Announces Presentation at the 2022 BIO International ConventionJune 2, 2022 | finance.yahoo.comBioMed Stocks On the Move: PDSB, NMLSF, TNXP, AIMLF; Leaders Report Latest Advances in Antiviral Vaccines, Novel Therapeutics for Oncology, and Autism and HealthTech WearablesJune 1, 2022 | markets.businessinsider.comMid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike HigherJune 1, 2022 | finance.yahoo.comTonix's stock jumps 43% on patent for experimental pox vaccinesJune 1, 2022 | benzinga.comMid-Morning Market Update: Markets Mixed; ISM Manufacturing PMI Rises To 56.1 In MayJune 1, 2022 | nasdaq.comPre-market Movers: TNXP, CNCE, TXMD, JAN, BFI…See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNXP CUSIPN/A CIK1430306 Webwww.tonixpharma.com Phone(212) 980-9155Fax212-923-5700Employees73Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/30/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$41.60 High Stock Price Forecast$64.00 Low Stock Price Forecast$19.20 Forecasted Upside/Downside+2,532.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($7.667740) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-48.46% Return on Assets-45.16% Debt Debt-to-Equity RatioN/A Current Ratio9.96 Quick Ratio9.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.08 per share Price / Book0.11Miscellaneous Outstanding Shares16,712,000Free Float16,378,000Market Cap$26.40 million OptionableOptionable Beta1.44 Tonix Pharmaceuticals Frequently Asked Questions Should I buy or sell Tonix Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tonix Pharmaceuticals stock. View analyst ratings for Tonix Pharmaceuticals or view top-rated stocks. What is Tonix Pharmaceuticals' stock price forecast for 2022? 2 equities research analysts have issued 12 month price targets for Tonix Pharmaceuticals' stock. Their TNXP stock forecasts range from $19.20 to $64.00. On average, they anticipate Tonix Pharmaceuticals' stock price to reach $41.60 in the next year. This suggests a possible upside of 2,532.9% from the stock's current price. View analysts' price targets for Tonix Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Tonix Pharmaceuticals' stock performed in 2022? Tonix Pharmaceuticals' stock was trading at $11.4464 at the beginning of the year. Since then, TNXP stock has decreased by 86.2% and is now trading at $1.58. View the best growth stocks for 2022 here. When is Tonix Pharmaceuticals' next earnings date? Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Tonix Pharmaceuticals. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its earnings results on Monday, May, 9th. The company reported ($1.60) EPS for the quarter, meeting analysts' consensus estimates of ($1.60). View Tonix Pharmaceuticals' earnings history. When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work? Shares of Tonix Pharmaceuticals reverse split before market open on Tuesday, May 17th 2022. The 1-32 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 17th 2022. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 3 shares after the split. Who are Tonix Pharmaceuticals' key executives? Tonix Pharmaceuticals' management team includes the following people: Dr. Seth Lederman M.D., Co-Founder, Pres, CEO & Chairman (Age 64, Pay $1.18M) (LinkedIn Profile)Mr. Bradley Saenger CPA, CPA, CFO & Treasurer (Age 48, Pay $595k)Dr. Gregory M. Sullivan M.D., Chief Medical Officer & Sec. (Age 56, Pay $616k)Mrs. Jessica Edgar Morris, Chief Operating OfficerDr. Herbert W. Harris M.D., Ph.D., Exec. VP of Translational MedicineDr. Bruce L. Daugherty M.B.A., Ph.D., Exec. VP of Research (Age 64)Ms. Siobhan Fogarty B.Sc., M.Sc., Exec. VP of Product Devel.Dr. Darryl Rideout Ph.D., Exec. VP of Experimental ChemistryDr. Anthony Macaluso Ph.D., Exec. VP of Strategic Devel.Dr. Daniel J. Clauw M.D., Consultant Who are some of Tonix Pharmaceuticals' key competitors? Some companies that are related to Tonix Pharmaceuticals include Entasis Therapeutics (ETTX), Paratek Pharmaceuticals (PRTK), Decibel Therapeutics (DBTX), Daré Bioscience (DARE), PDS Biotechnology (PDSB), Xynomic Pharmaceuticals (XYNO), Xeris Biopharma (XERS), Enochian Biosciences (ENOB), Leap Therapeutics (LPTX), Assembly Biosciences (ASMB), Summit Therapeutics (SMMT), ImmunoPrecise Antibodies (IPA), Checkpoint Therapeutics (CKPT), Anixa Biosciences (ANIX) and NervGen Pharma (NGENF). View all of TNXP's competitors. What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA). What is Tonix Pharmaceuticals' stock symbol? Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP." How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tonix Pharmaceuticals' stock price today? One share of TNXP stock can currently be purchased for approximately $1.58. How much money does Tonix Pharmaceuticals make? Tonix Pharmaceuticals (NASDAQ:TNXP) has a market capitalization of $26.40 million. The company earns $-92.29 million in net income (profit) each year or ($7.667740) on an earnings per share basis. How many employees does Tonix Pharmaceuticals have? Tonix Pharmaceuticals employs 73 workers across the globe. How can I contact Tonix Pharmaceuticals? Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The official website for Tonix Pharmaceuticals is www.tonixpharma.com. The company can be reached via phone at (212) 980-9155, via email at [email protected], or via fax at 212-923-5700. This page (NASDAQ:TNXP) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
